For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.
Jeffrey Anderson
Douglas Zipes
JEFFREY ANDERSON, University of Utah, Salt Lake City
COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis
REFERENCE: Abstract 1020-89, American College
Carlo Pappone, San Raffaele University Hospital, Milan
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
The use of circumferential
Post a comment